In 2020, several scientists from Heidelberg academic institutions have again made it to the top: They are among the leading one percent of the world's highly cited researchers in their respective fields. This means that scientists whose work is cited particularly frequently by their peers are considered to be highly recognized and important in their field. The citation frequency is therefore one of the most important measurements for classifying the influence and performance of individual researchers.
Ralf Bartenschlager (DKFZ and Heidelberg University Hospital) paved the way with his groundbreaking research results on the hepatitis C virus to develop effective drugs against the dangerous pathogen (category microbiology).
Epidemiologist Hermann Brenner (DKFZ and NCT Heidelberg) is considered a leading expert in the evaluation of cancer prevention measures (Cat. Cross Fields).
Eran Elinav is an expert on the health effects of the intestinal microbiome. He works at the Weizmann Institute in Israel and heads a research department at the DKFZ that focuses on the influence of the microbiome on the development of cancer (Cat. Molecular Biology and Genetics).
Andreas von Deimling (DKFZ and Heidelberg University Hospital) is internationally renowned for the development of diagnostic antibodies that can be used to detect cancer-specific mutations and are used worldwide to better assess brain tumors (Cat. Neurosciences).
Nuclear medicine specialist Uwe Haberkorn (DKFZ and Heidelberg University Hospital) is developing methods for using PET-CT to monitor the response to and progress of therapy in various types of cancer (Cat. Cross Fields).
Mathias Heikenwälder researches how chronic inflammation causes cancer and how these processes can be stopped (Cat. Cross Fields).
David Jones, Andrey Korshunov and Stefan Pfister achieved their ranking through interdisciplinary research (Cross Fields cat.): The scientists, who also work at the Hopp Children's Tumor Center "KiTZ", are among the world's most renowned experts on the molecular genetics of childhood brain tumors. This means that they also have a considerable influence on the treatment of young patients and therefore also publish in specialist journals for clinical medicine.
The neurologist Michael Platten, DKFZ and Medical Faculty Mannheim of the University of Heidelberg, develops immunotherapies against brain tumors and investigates the role of the metabolism of the amino acid tryptophan in cancer (Cat. Cross Fields).
Oliver Stegle (DKFZ and EMBL) develops methods for the analysis of high-throughput data. One focus is on methods for studying genetic variations in individual cells (Cat. Cross Fields).
The neurologist Wolfgang Wick (DKFZ and Heidelberg University Hospital) is investigating the molecular mechanisms of possible targeted therapies against glioblastoma (Cat. Cross Fields).
Markus W. Büchler, Spokesperson for the Surgery Clinic (Centre) of Heidelberg University Hospital and Medical Director of its Clinic for General, Abdominal and Transplant Surgery
Hartmut Goldschmid, Head of the Multiple Myeloma Section (Heidelberg Myeloma Center) of Heidelberg University Hospital and the National Center for Tumor Diseases Heidelberg
Werner Hacke, Senior Professor at the Medical Faculty Heidelberg of Heidelberg University
Stephen K. Hashmi, Research group leader at the Institute of Organic Chemistry at Heidelberg University
Hugo A. Katus, Senior Professor at the Medical Faculty Heidelberg of Heidelberg University
Andreas Meyer-Lindenberg, Head of the Executive Board of the Central Institute for Mental Health in Mannheim and Medical Director of its Psychiatry and Psychotherapy Clinic as well as Professor at the Medical Faculty Mannheim of Heidelberg University
Rolf-Detlef Treede, Head of the Department of Neurophysiology and member of the Translational Neuroscience research focus at the Medical Faculty Mannheim of Heidelberg University
Original News: